ClinicalTrials.gg
CompletedNCT00630877Updated Oct 9, 2009Results posted

Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin

A Phase 3 interventional study of Niacin extended-release (NER) and Niacin extended-release (NER) placebo in Dyslipidemia, sponsored by Abbott. Completed at 41 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-10-09.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
276
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 18 studies testing niacin in Dyslipidemias — none open to participants now, none under way, none of them phase 3. Niacin · Dyslipidemias.

Enrollment
2nd of 17
276 · median 30
Started
2008
with 3 others
Phase 3
5 of 18
none open now
Registered
5th of 18
by date
Lead sponsor
1 of 18
Abbott

Among the 18 studies testing niacin in Dyslipidemias, this one is the 2nd largest by enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2008, is one of 5 in phase 3, and was the 5th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

None of the 18 studies testing niacin in Dyslipidemias is open now. The open studies under Dyslipidemias, anywhere →

About niacin

Niacin: first FDA approval 1957 (WAMPOCAP), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing niacin in Dyslipidemias as a file.
02

Study summary

The primary purpose of this study was to evaluate the psychometric characteristics (reliability, validity, and responsiveness) of a Flushing ASsessment Tool (FAST) in subjects receiving niacin extended-release (NER) plus aspirin (ASA) daily for 6 weeks.

The FAST is a questionnaire that was developed to provide a detailed assessment of flushing symptoms and their impact in patients receiving niacin therapy. The effect of aspirin on flushing symptoms, as measured by the FAST, was also evaluated.

Read the detailed description

This study was designed to evaluate the psychometric characteristics of the FAST questionnaire.

The FAST is a self-administered questionnaire, completed using a hand-held electronic data capture device (LogPad e-diary). Subjects recorded the start and stop date and time of each flushing event, the presence and severity of individual flushing symptoms (redness, warmth, tingling and/or itching), and an overall assessment of their flushing experience.

Evaluation of the psychometric characteristics of the FAST was based on 3 primary data analyses: 1 ) test-retest reliability based on the intraclass correlation coefficient; 2) construct validity based on Spearman correlation coefficients; and 3) responsiveness based on changes in FAST scores. The mean and maximum severity of flushing events, as measured by the FAST, were the primary variables evaluated in each of the 3 data analyses mentioned above. Psychometric analyses were performed blinded to treatment group assignment.

03

Conditions studied

  • Dyslipidemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be 18 years of age or older.
  • If female, subject is either not of , defined as for at least one year or surgically sterile, or is of childbearing potential and must agree to practice for the duration of the study.
  • Have dyslipidemia as demonstrated by laboratory results.

Exclusion criteria

Exclusion Criteria:

  • Have glycosylated () >= 9.0%.
  • Have nephrotic syndrome, dysproteinemias, or severe renal failure ( [GFR] \< 30 mL/minute, as calculated from ).
  • Have had unstable angina or an acute myocardial infarction (MI) within three months of the Screening Visit.
  • Have had severe peripheral artery disease as evidenced by intermittent claudication within three months of the Screening Visit.
  • Have had uncontrolled cardiac arrhythmias within three months of the Screening Visit.
  • Have symptomatic heart failure defined as dyspnea at rest or with exertion (mild peripheral edema is not exclusionary).
  • Have a systolic blood pressure measurement of > 180 mmHg or a diastolic blood pressure measurement of > 110 mmHg at the Screening or Baseline Visit
  • Have active gout or uric acid >= 11 mg/dL.
  • Have a history of hepatitis (acute or chronic), obstructive liver disease, or (ALT; serum glutamic pyruvic transaminase [SGPT]) or aspartate aminotransferase (AST; serum glutamic oxaloacetic transaminase [SGOT]) values >= 1.3 times the (ULN) at the Screening Visit.
  • Have creatine phosphokinase (CPK) >= 3 x ULN at the Screening Visit.
  • Have used an study drug or participated in an investigational study within 30 days of the Screening Visit.
  • Have a health condition or laboratory abnormality (inclusive of laboratory results at Screening Visit), which, in the opinion of the Investigator, may be adversely affected by the procedures or study medications in this study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
276 participants (actual)

Study arms

  • Experimental
    NER/ASA

    Drug: Niacin extended-release (NER) · Drug: Aspirin (ASA)

  • Experimental
    NER/ASA Placebo

    Drug: Niacin extended-release (NER) · Drug: Aspirin (ASA) placebo

  • Experimental
    NER Placebo/ASA Placebo

    Drug: Niacin extended-release (NER) placebo · Drug: Aspirin (ASA) placebo

Interventions

  • Tablets administered once daily for 6 weeks; titrated to a maximum dose of 2000 mg

    Also known as: ABT-919, Niaspan

  • DrugNiacin extended-release (NER) placebo

    Tablets administered once daily for 6 weeks

  • Tablets (325 mg) administered once daily for 6 weeks

    Also known as: acetylsalicylic acid

  • DrugAspirin (ASA) placebo

    Tablets administered once daily for 6 weeks

06

What researchers measure

Primary outcomes

  1. Flushing ASsessment Tool (FAST) Test-retest Reliability--mean Flushing Severity Score

    Test-retest reliability of the mean flushing severity score was evaluated. The intraclass correlation coefficient comparing flushing severity scores for Week 1 and Week 2 was examined to determine test-retest reliability. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe.

    Time frame: Week 1 to Week 2

  2. FAST Test-retest Reliability--maximum Flushing Severity Score

    Test-retest reliability of the maximum flushing severity score was evaluated. The intraclass correlation coefficient comparing flushing severity scores for Week 1 and Week 2 was examined to determine test-retest reliability. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe.

    Time frame: Week 1 to Week 2

  3. FAST Cross-sectional Construct Validity--mean Flushing Severity Score

    The relationship between mean flushing severity and overall flushing troublesomeness was evaluated by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Overall flushing troublesomeness was assessed using the FAST on a scale of 1 to 10, with 10 being the most troublesome.

    Time frame: Week 1

  4. FAST Cross-sectional Construct Validity--maximum Flushing Severity Score

    The relationship between maximum flushing severity and overall flushing troublesomeness was evaluated by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Overall flushing troublesomeness was assessed using the FAST on a scale of 1 to 10, with 10 being the most troublesome.

    Time frame: Week 1

  5. FAST Longitudinal Construct Validity--mean Flushing Severity Score

    The relationship between the change in mean flushing severity scores from Week 1 to Week 2, and the subject-rated overall treatment effect scale administered at Week 2, was assessed by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. The overall treatment effect was assessed on a scale of 1 (symptoms are worse since study start), 2 (symptoms are about the same since study start), or 3 (symptoms are better since study start).

    Time frame: Week 1 to Week 2

  6. FAST Longitudinal Construct Validity--maximum Flushing Severity Score

    The relationship between the change in maximum flushing severity scores from Week 1 to Week 2, and the subject-rated overall treatment effect scale administered at Week 2, was assessed by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. The overall treatment effect was assessed on a scale of 1 (symptoms are worse since study start), 2 (symptoms are about the same since study start), or 3 (symptoms are better since study start).

    Time frame: Week 1 to Week 2

  7. FAST Responsiveness--mean Flushing Severity Score

    The change in mean flushing severity scores from study start to Day 43 was compared in subjects classified as responders vs. nonresponders. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Changes in mean flushing severity scores were negative if flushing symptoms improved and positive if flushing symptoms worsened.

    Time frame: Study start to Day 43

  8. FAST Responsiveness--maximum Flushing Severity Score

    The change in maximum flushing severity scores from study start to Day 43 was compared in subjects classified as responders vs. nonresponders. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Changes in maximum flushing severity scores were negative if flushing symptoms improved and positive if flushing symptoms worsened.

    Time frame: Study start to Day 43

Secondary outcomes

  1. Maximum Severity of Flushing Events Overall During the Study

    The severity of flushing events was assessed as none, mild, moderate, severe, or very severe using the FAST. The maximum severity of flushing events overall during the study was compared among treatment groups.

    Time frame: Week 1 to Week 6

07

Results

Posted Oct 9, 2009

Participant flow

Subjects were enrolled at 41 sites in the United States between February and June, 2008.

Participant flow — Overall Study
MilestoneNER/ASANER/ASA PlaceboNER Placebo/ASA Placebo
Started919090
Completed727580
Not completed191510
Withdrew: Adverse event1187
Withdrew: Withdrawal by subject340
Withdrew: Lost to follow-up200
Withdrew: Noncompliance231
Withdrew: Protocol violation101
Withdrew: Personal reasons001

Outcome measures

PrimaryFlushing ASsessment Tool (FAST) Test-retest Reliability--mean Flushing Severity Score

Test-retest reliability of the mean flushing severity score was evaluated. The intraclass correlation coefficient comparing flushing severity scores for Week 1 and Week 2 was examined to determine test-retest reliability. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe.

Time frame:
Week 1 to Week 2
Reported as:
Number · Intraclass correlation coefficient
Flushing ASsessment Tool (FAST) Test-retest Reliability--mean Flushing Severity Score
Intraclass correlation coefficientSubjects With Stable Flushing Symptoms
Flushing ASsessment Tool (FAST) Test-retest Reliability--mean Flushing Severity Score0.75
SecondaryMaximum Severity of Flushing Events Overall During the Study

The severity of flushing events was assessed as none, mild, moderate, severe, or very severe using the FAST. The maximum severity of flushing events overall during the study was compared among treatment groups.

Time frame:
Week 1 to Week 6
Reported as:
Number · Percentage of subjects
Maximum Severity of Flushing Events Overall During the Study
Percentage of subjectsNER/ASANER/ASA PlaceboNER Placebo/ASA Placebo
None261437
Mild231638
None/Mild493075
Moderate343122
Severe17322
Very Severe070
Statistical analysis
  • NER/ASA vs NER/ASA Placebo · Cochran-Mantel-Haenszel · p = <0.001
PrimaryFAST Test-retest Reliability--maximum Flushing Severity Score

Test-retest reliability of the maximum flushing severity score was evaluated. The intraclass correlation coefficient comparing flushing severity scores for Week 1 and Week 2 was examined to determine test-retest reliability. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe.

Time frame:
Week 1 to Week 2
Reported as:
Number · Intraclass correlation coefficient
FAST Test-retest Reliability--maximum Flushing Severity Score
Intraclass correlation coefficientSubjects With Stable Flushing Symptoms
FAST Test-retest Reliability--maximum Flushing Severity Score0.40
PrimaryFAST Cross-sectional Construct Validity--mean Flushing Severity Score

The relationship between mean flushing severity and overall flushing troublesomeness was evaluated by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Overall flushing troublesomeness was assessed using the FAST on a scale of 1 to 10, with 10 being the most troublesome.

Time frame:
Week 1
Reported as:
Number · Spearman correlation coefficient
FAST Cross-sectional Construct Validity--mean Flushing Severity Score
Spearman correlation coefficientModified Intent-to-Treat (m-ITT) Population
FAST Cross-sectional Construct Validity--mean Flushing Severity Score0.64
Statistical analysis
  • Modified Intent-to-Treat (m-ITT) Population · Spearman rank-order correlation · p = <0.0001
PrimaryFAST Cross-sectional Construct Validity--maximum Flushing Severity Score

The relationship between maximum flushing severity and overall flushing troublesomeness was evaluated by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Overall flushing troublesomeness was assessed using the FAST on a scale of 1 to 10, with 10 being the most troublesome.

Time frame:
Week 1
Reported as:
Number · Spearman correlation coefficient
FAST Cross-sectional Construct Validity--maximum Flushing Severity Score
Spearman correlation coefficientModified Intent-to-Treat (m-ITT) Population
FAST Cross-sectional Construct Validity--maximum Flushing Severity Score0.66
Statistical analysis
  • Modified Intent-to-Treat (m-ITT) Population · Spearman rank-order correlation · p = <0.0001
PrimaryFAST Longitudinal Construct Validity--mean Flushing Severity Score

The relationship between the change in mean flushing severity scores from Week 1 to Week 2, and the subject-rated overall treatment effect scale administered at Week 2, was assessed by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. The overall treatment effect was assessed on a scale of 1 (symptoms are worse since study start), 2 (symptoms are about the same since study start), or 3 (symptoms are better since study start).

Time frame:
Week 1 to Week 2
Reported as:
Number · Spearman correlation coefficient
FAST Longitudinal Construct Validity--mean Flushing Severity Score
Spearman correlation coefficientModified Intent-to-Treat (m-ITT) Population
FAST Longitudinal Construct Validity--mean Flushing Severity Score-0.44
Statistical analysis
  • Modified Intent-to-Treat (m-ITT) Population · Spearman rank-order correlation · p = <0.0001
PrimaryFAST Longitudinal Construct Validity--maximum Flushing Severity Score

The relationship between the change in maximum flushing severity scores from Week 1 to Week 2, and the subject-rated overall treatment effect scale administered at Week 2, was assessed by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. The overall treatment effect was assessed on a scale of 1 (symptoms are worse since study start), 2 (symptoms are about the same since study start), or 3 (symptoms are better since study start).

Time frame:
Week 1 to Week 2
Reported as:
Number · Spearman correlation coefficient
FAST Longitudinal Construct Validity--maximum Flushing Severity Score
Spearman correlation coefficientModified Intent-to-Treat (m-ITT) Population
FAST Longitudinal Construct Validity--maximum Flushing Severity Score-0.42
Statistical analysis
  • Modified Intent-to-Treat (m-ITT) Population · Spearman rank-order correlation · p = <0.0001
PrimaryFAST Responsiveness--mean Flushing Severity Score

The change in mean flushing severity scores from study start to Day 43 was compared in subjects classified as responders vs. nonresponders. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Changes in mean flushing severity scores were negative if flushing symptoms improved and positive if flushing symptoms worsened.

Time frame:
Study start to Day 43
Reported as:
Number · Units on a scale
FAST Responsiveness--mean Flushing Severity Score
Units on a scaleRespondersNonresponders
FAST Responsiveness--mean Flushing Severity Score-0.510.15
Statistical analysis
  • Responders vs Nonresponders · Independent groups t-test · p = 0.002
PrimaryFAST Responsiveness--maximum Flushing Severity Score

The change in maximum flushing severity scores from study start to Day 43 was compared in subjects classified as responders vs. nonresponders. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Changes in maximum flushing severity scores were negative if flushing symptoms improved and positive if flushing symptoms worsened.

Time frame:
Study start to Day 43
Reported as:
Number · Units on a scale
FAST Responsiveness--maximum Flushing Severity Score
Units on a scaleRespondersNonresponders
FAST Responsiveness--maximum Flushing Severity Score-1.85-0.18
Statistical analysis
  • Responders vs Nonresponders · Independent groups t-test · p = <0.001

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NER/ASA———
NER/ASA Placebo———
NER Placebo/ASA Placebo———
Most frequent serious events
Most frequent serious events
EventNER/ASANER/ASA PlaceboNER Placebo/ASA Placebo
Myocardial infarctionCardiac disorders0/911/900/90
Right renal cystRenal and urinary disorders0/910/901/90
NephrolithiasisRenal and urinary disorders0/910/901/90
Adenomatous polyposisCongenital, familial and genetic disorders0/910/901/90
Non-cardiac chest painGeneral disorders1/910/900/90
Most frequent other events
Showing 10 of 16
Most frequent other events
EventNER/ASANER/ASA PlaceboNER Placebo/ASA Placebo
FlushingVascular disorders68/9178/9056/90
DiarrheaGastrointestinal disorders2/917/905/90
HeadacheNervous system disorders3/911/907/90
NauseaGastrointestinal disorders4/912/902/90
VomitingGastrointestinal disorders3/912/902/90
Upper respiratory tract infectionInfections and infestations3/912/902/90
FatigueGeneral disorders1/912/900/90
SinusitisInfections and infestations1/912/901/90
HyperglycemiaMetabolism and nutrition disorders0/912/900/90
Muscle spasmsMusculoskeletal and connective tissue disorders1/912/900/90

Baseline characteristics

Age Continuous
Age Continuous(years)NER/ASANER/ASA PlaceboNER Placebo/ASA PlaceboTotal
Mean54.1 ± 11.6853.7 ± 12.7452.9 ± 12.2653.6 ± 12.20
Sex: Female, Male
Sex: Female, Male(Participants)NER/ASANER/ASA PlaceboNER Placebo/ASA PlaceboTotal
Female424142125
Male494948146
Region of Enrollment
Region of Enrollment(participants)NER/ASANER/ASA PlaceboNER Placebo/ASA PlaceboTotal
United States919090271
08

Study locations

41 sites
  • Birmingham, Alabama 35209, United States
  • Anaheim, California 92801, United States
  • Walnut Creek, California 94598, United States
  • Denver, Colorado 80212, United States
  • Brooksville, Florida 34613, United States
  • Daytona Beach, Florida 32127, United States
  • Hollywood, Florida 33023, United States
  • Jacksonville, Florida 32216, United States
  • Largo, Florida 33770, United States
  • Miami, Florida 33126, United States
  • Pembroke Pines, Florida 33026, United States
  • Boise, Idaho 83704, United States
  • Chicago, Illinois 60610, United States
  • Arkansas City, Kansas 67005, United States
  • Topeka, Kansas 66608, United States
  • Wichita, Kansas 67203, United States
  • Wichita, Kansas 67207, United States
  • St Louis, Missouri 63141, United States
  • St. Louis, Missouri 63141, United States
  • Las Vegas, Nevada 89146, United States
  • Durham, North Carolina 27704, United States
  • High Point, North Carolina 27262, United States
  • Salisbury, North Carolina 28144, United States
  • Statesville, North Carolina 28677, United States
  • Cincinnati, Ohio 45242, United States
  • Portland, Oregon 97239, United States
  • Duncansville, Pennsylvania 16635, United States
  • Harleysville, Pennsylvania 19438, United States
  • Pittsburgh, Pennsylvania 15206, United States
  • Greer, South Carolina 29651, United States
  • Austin, Texas 78752, United States
  • Carrollton, Texas 75006, United States
  • Dallas, Texas 75251, United States
  • San Antonio, Texas 78217, United States
  • San Antonio, Texas 78224, United States
  • Magna, Utah 84044, United States
  • Murray, Utah 84107, United States
  • Sandy, Utah 84094, United States
  • Gig Harbor, Washington 98335, United States
  • Menomonee Falls, Wisconsin 53051, United States
  • Milwaukee, Wisconsin 53209, United States
09

References and documents

Publications

  • Kawata AK, Revicki DA, Thakkar R, Jiang P, Krause S, Davidson MH, Punzi HA, Padley RJ. Flushing ASsessment Tool (FAST): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy. Clin Drug Investig. 2009;29(4):215-29. doi: 10.2165/00044011-200929040-00001. PubMed 19301936 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2009, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 29, 2008
First posted
Mar 7, 2008
Start
Feb 2008
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Results first posted
Oct 9, 2009
Last update
Oct 9, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00630877
Lead sponsor
Abbott
First posted
Mar 7, 2008
Start date
Feb 2008
Primary completion
Jun 2008
Completion
Jun 2008
Results posted
Oct 9, 2009
Last update
Oct 9, 2009

Study contacts

Roopal Thakkar, MD
study director · Abbott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Niacin · Aspirin

Start the discussion